A Prospective, Multi-national, Cross-sectional Study on a Risk-factor Guided Approach to Interstitial Lung Disease Screening in Patients With Rheumatoid Arthritis at Higher Risk for ILD Using High Resolution Computed Tomography

Status: Completed
Location: See all (28) locations...
Study Type: Observational
SUMMARY

The overall aim of the study is to develop and validate a Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD) clinical prediction model (screening tool) based on risk factors to guide screening for ILD in patients with RA using High Resolution Computed Tomography (HRCT).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients with RA according to 1987 American College of Rheumatology (ACR) or 2010 ACR / European League Against Rheumatism (EULAR) classification of RA, with any RA duration

• Patient must have ≥ 2 of the following risk factors for ILD (i.e., any 2 or more):

‣ Male

⁃ Current or previous smoker

⁃ Age of ≥ 60 years at RA diagnosis

⁃ Rheumatoid factor high-positive (titer \> 3x upper limit of normal) AND/OR anti-cyclic citrullinated peptide (anti-CCP) high-positive (titer \> 3x upper limit of normal) at RA diagnosis or any time after RA diagnosis

⁃ High/severe RA disease activity score at screening visit or within 12 months of screening visit, as defined with any of the following measures: Disease Activity Score-28 (DAS-28), Clinical Disease Activity Index (CDAI), Routine Assessment of Patient Index Data 3 (RAPID-3), Simple Disease Activity Index (SDAI), Patient Activity Scale (PAS), PAS-II

⁃ Presence or history of these extra-articular manifestations of RA: vasculitis, Felty's syndrome, secondary Sjogren's syndrome, cutaneous rheumatoid nodules, serositis and/or scleritis/uveitis

Locations
United States
California
Stanford University School of Medicine
Palo Alto
Colorado
University of Colorado
Aurora
Massachusetts
Harvard Medical School - Brigham and Women's Hospital
Boston
Michigan
University of Michigan Health System
Ann Arbor
Nebraska
University of Nebraska Medical Center
Omaha
Other Locations
France
Clinique de l'infirmerie Protestante
Caluire-et-cuire
Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Cochin
Paris
Hopital Bichat, APHP
Paris
Centre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord
Saint-priest-en-jarez
Germany
Rheumazentrum Prof. Dr. med Gunther Neeck
Bad Doberan
Charite - Universitaetsmedizin Berlin - Campus Charite Mitte (CCM)
Berlin
Dr. Jochen Walter MD, Office Of
Rendsburg
Italy
Di.M.I. Irccs A.O.S.Martino (U.O.Clinica Reumatological)
Genova
Fondazione Irccs Ca' Granda Ospedale Maggioe Policlinico Di Milano
Milan
Azienda Ospedaliero-Universitaria Policlinico di Modena
Modena
AOU di Padova
Padua
Fondazione Policlinico Universitario - Agostino Gemelli, Universita Cattolica del Sacro Cuore
Roma
Azienda Ospedaliera Universitaria Integrata di Verona - Ospedale Borgo Roma
Verona
Spain
Hospital Clinic de Barcelona (Hospital Clinic i Provincial)
Barcelona
Hospital Universitario Reina Sofia
Córdoba
Hospital Universitario 12 de Octubre
Madrid
Hospital Universitario Ramon y Cajal
Madrid
Hospital General Universitario De Valencia
Valencia
Hospital Do Meixoeiro
Vigo
United Kingdom
Nottingham University Hospitals NHS Trust - Nottingham City Hospital
Nottingham
Southampton General Hospital - University Hospital Southampton NHS Foundation Trust
Southampton
Leeds University
West Yorkshire
Southend University Hospital - Mid Essex Hospital Services NHS Trust
Westcliff-on-sea
Time Frame
Start Date: 2023-11-27
Completion Date: 2025-06-26
Participants
Target number of participants: 1304
Treatments
Patients with Rheumatoid Arthritis (RA)
RA and 2 or more risk factors for developing Interstitial Lung Disease (ILD)
Sponsors
Leads: Boehringer Ingelheim

This content was sourced from clinicaltrials.gov